7. DISEASE MODEL AND SOME LABORATORY INDICATORS OF ATO CYCLE HEMODIALYSIS PATIENTS AT TRANSPORT HOSPITAL IN 2024-2025
Main Article Content
Abstract
Objectives: To describe disease patterns and analyze the association between dialysis duration, age, and hematological–biochemical indices in chronic hemodialysis patients.
Methods: A cross-sectional study was conducted on 125 patients at Transport Hospital (2023–2024). Clinical, hematological, and biochemical data were compared between patients with <5 vs. >5 years of dialysis, and multivariate regression was performed with age and dialysis duration.
Results: Hypertension surpassed glomerulonephritis as the leading cause of end-stage renal disease. Patients with shorter dialysis duration had more comorbidities (hypertension 68.3%, diabetes 23.8%). Longer dialysis duration correlated positively with reticulocyte ratio (Coef = 0.03; p<0.001), reticulocyte hemoglobin content (Coef = 0.08; p<0.01), and ferritin (Coef = 28.74; p<0.001). Older age correlated inversely with urea, creatinine, Na⁺, K⁺, and albumin (p<0.05).
Conclusions: The disease spectrum among hemodialysis patients is shifting, with rising prevalence of hypertension and comorbidities. Personalized management strategies should be tailored according to age and hematologic–biochemical indices.
Article Details
Keywords
chronic hemodialysis, disease pattern, hematological indices, biochemical indices.
References
[2] Thurlow JS, et al. Global Epidemiology of End-Stage Kidney Disease and Disparities in Kidney Replacement Therapy. Am J Nephrol. 2021;52(2):98-107.
[3] Liyanage T, et al. Prevalence of chronic kidney disease in Asia: a systematic review and analysis. BMJ Glob Health. 2022;7(1).
[4] Nguyễn Lê Thanh Trúc, et al. Tình trạng thiếu máu ở bệnh nhân bệnh thận mạn tại Việt Nam. Tạp chí Y học Việt Nam. 2021.
[5] Zhang L, et al. Prevalence of chronic kidney disease in China. JAMA Intern Med. 2023;183(4):298-310.
[6] Thurlow JS, et al. Global Epidemiology of End-Stage Kidney Disease. Am J Nephrol. 2021;52(2):98-107.
[7] Cockwell P, Fisher LA. The global burden of chronic kidney disease. Lancet. 2020;395(10225):662-664.
[8] Murali KM, Lonergan M. Breaking the adherence barriers: Strategies to improve treatment adherence in dialysis patients. Semin Dial. 2020.
[9] Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012;23(10):1631-1634.
[10] Fishbane S, Spinowitz B. Update on Anemia in ESRD. Am J Kidney Dis. 2018;71(3):423-435.
[11] Lin YL, Hsu BG. Assessment of uremic sarcopenia in dialysis patients. Tzu Chi Med J. 2022;34(2):182-191.
[12] Sun J, et al. Association between serum albumin level and mortality in CKD. Am J Med Sci. 2021;361(4):451-460.
[13] Pecoits-Filho R, Lindholm B, Stenvinkel P. The malnutrition, inflammation, and atherosclerosis (MIA) syndrome. Nephrol Dial Transplant. 2002;17 Suppl 11:28-31.